Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability ; volume:15 ; number:1 ; day:4 ; month:1 ; year:2024 ; pages:1-16 ; date:12.2024
Nature Communications ; 15, Heft 1 (4.1.2024), 1-16, 12.2024
- Urheber
-
Gorman, Jason
Cheung, Crystal Sao-Fong
Duan, Zhijian
Ou, Li
Wang, Maple
Chen, Xuejun
Cheng, Cheng
Biju, Andrea
Sun, Yaping
Wang, Pengfei
Yang, Yongping
Zhang, Baoshan
Boyington, Jeffrey C.
Bylund, Tatsiana
Charaf, Sam
Chen, Steven J.
Du, Haijuan
Henry, Amy R.
Liu, Tracy
Sarfo, Edward K.
Schramm, Chaim A.
Shen, Chen-Hsiang
Stephens, Tyler
Teng, I-Ting
Todd, John-Paul
Tsybovsky, Yaroslav
Verardi, Raffaello
Wang, Danyi
Wang, Shuishu
Wang, Zhantong
Zheng, Cheng-Yan
Zhou, Tongqing
Douek, Daniel C.
Mascola, John R.
Ho, David D.
Ho, Mitchell
Kwong, Peter D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-44534-y
- URN
-
urn:nbn:de:101:1-2024031910371077882826
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gorman, Jason
- Cheung, Crystal Sao-Fong
- Duan, Zhijian
- Ou, Li
- Wang, Maple
- Chen, Xuejun
- Cheng, Cheng
- Biju, Andrea
- Sun, Yaping
- Wang, Pengfei
- Yang, Yongping
- Zhang, Baoshan
- Boyington, Jeffrey C.
- Bylund, Tatsiana
- Charaf, Sam
- Chen, Steven J.
- Du, Haijuan
- Henry, Amy R.
- Liu, Tracy
- Sarfo, Edward K.
- Schramm, Chaim A.
- Shen, Chen-Hsiang
- Stephens, Tyler
- Teng, I-Ting
- Todd, John-Paul
- Tsybovsky, Yaroslav
- Verardi, Raffaello
- Wang, Danyi
- Wang, Shuishu
- Wang, Zhantong
- Zheng, Cheng-Yan
- Zhou, Tongqing
- Douek, Daniel C.
- Mascola, John R.
- Ho, David D.
- Ho, Mitchell
- Kwong, Peter D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
![Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
Broadly Neutralizing Antibodies for HIV Eradication
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient
Heparin Neutralizing Activity (HNA) in Clinical Practice
Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
Broadly Neutralizing Antibodies for HIV Eradication
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient
Heparin Neutralizing Activity (HNA) in Clinical Practice
Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
Broadly Neutralizing Antibodies for HIV Eradication
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Development of neutralizing and non-neutralizing antibodies targeting known and novel epitopes on Clostridioides difficile Toxin B
Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient